Impact of a Health Management Program on Healthcare Outcomes Among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis

Advances in Therapy - United States
doi 10.1007/s12325-018-0690-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Safety and Efficacy of Alpha-1-Antitrypsin Augmentation Therapy in the Treatment of Patients With Alpha-1-Antitrypsin Deficiency

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Benefits Among Patients With Alpha-1 Antitrypsin Deficiency Enrolled in a Disease Management and Prevention Program

Chronic Obstructive Pulmonary Diseases
PulmonaryRespiratory Medicine
2017English

Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease

Annals of the American Thoracic Society
PulmonaryRespiratory Medicine
2016English

Alpha-1-Antitrypsin Deficiency

2020English

Alpha-1 Antitrypsin Deficiency

Journal of insurance medicine (New York, N.Y.)
Medicine
2015English

Alpha‐1‐Antitrypsin Deficiency

English

Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy

Human Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2015English

Alpha-1 Antitrypsin Deficiency in Patients With Chronic Hepatitis

Turkish Journal of Gastroenterology
Gastroenterology
2012English

Health-Related Quality of Life in Patients With Alpha-1 Antitrypsin Deficiency: A Cross Sectional Study

Archivos de Bronconeumologia
PulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy